AP NEWS

Myriad to Present New Data from Its Industry-Leading Portfolio of Genetic Tests for Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

November 12, 2018

SALT LAKE CITY, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that 10 studies will be featured at the San Antonio Breast Cancer Symposium (SABCS) being held Dec. 4-8, 2018 in San Antonio, Tx. Data from four Myriad products will be featured including myRisk® Hereditary Cancer, riskScore™, EndoPredict®, and myChoice HRD™.“More than 3 million American women have breast cancer, and there is critical need to transform the standard of care and improve outcomes for these patients,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics. “We are excited to be presenting new data across multiple genetic tests at SABCS and to highlight our progress in advancing precision medicine for women with breast cancer.”Please visit Myriad at Booth #1001 to learn more about genetic testing for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news and updates by using the hashtag #SABCS18.

Featured Research at SABCS 2018 -------------------------------------------------------------------------------------------------------------- Product Abstract Logistical Details ----------------------------- ---------------------------------------- --------------------------------------- Defining the spectrum of germline Poster (P1-10-01) variants among African-American patients Wednesday, Dec. 5, 2018, 5:00-7:00 p.m. with triple negative breast cancer. ---------------------------------------- --------------------------------------- Development and validation of a polygenic score to predict breast cancer Poster (P5-10-02) risk in unaffected Hispanic women Friday, Dec. 7, 2018, negative for mutations on a multi-gene 5:00 - 6:00 p.m. myRisk® Hereditary Cancer and hereditary cancer panel. riskScore™ ---------------------------------------- --------------------------------------- Associations between clinical factors in Poster (P4-09-04) v7.02 of the Tyrer-Cuzick model and a Friday, Dec. 7, 2018. 7:30 - 9:00 a.m. SNP-based residual risk score. ---------------------------------------- --------------------------------------- Genetic testing significantly improves Poster (P4-03-04) the accuracy of breast cancer risk Friday, Dec. 7, 2018, assessment compared to use of the 7:30-9:00 a.m. Tyrer-Cuzick risk model. -------------------------------------------------------------------------------------------------------------- RESCUE: Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer - A prospective health Poster (OT1-12-03) care study on risk assessment by the Wednesday, Dec. 5, 2018, 5:00-7:00 p.m. clinicomolecular test EndoPredict and long-term patient outcome in early luminal breast cancer. ---------------------------------------- --------------------------------------- Change in therapeutic management after EndoPredict assay in Mexican Poster (P2-08-54) premenopausal patients with early-stage Thursday, Dec. 6, 2018, 7:30-9:00 a.m. hormone receptor-positive breast cancer. EndoPredict® ---------------------------------------- --------------------------------------- Prediction of distant recurrence by EndoPredict in patients with ER-positive, HER2-negative breast cancer Poster (P2-08-04) who received adjuvant endocrine therapy Thursday, Dec. 6, 2018, 7:30-9:00 a.m. plus chemotherapy or endocrine therapy alone. ---------------------------------------- --------------------------------------- Prediction of distant recurrence using EndoPredict among women with Poster (P4-08-05) ER-Positive, HER2-negative breast cancer Friday, Dec. 7, 2018, treated with endocrine therapy only with 7:30-9:00 a.m. 15-year follow up. -------------------------------------------------------------------------------------------------------------- Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of Poster (P1-06-07) carboplatin compared with docetaxel for Wednesday, Dec. 5, 2018, 5:00-7:00 p.m. patients with metastatic or recurrent locally advanced triple negative or myChoice HRD™ BRCA1/2 breast cancer. ---------------------------------------- --------------------------------------- Impact of molecular subtypes on long Poster (P4-08-06) term outcomes in triple negative breast Friday, Dec. 7, 2018, cancer patients treated with adjuvant AC 7:30-9:00 a.m. chemotherapy on SWOG S9313. --------------------------------------------------------------------------------------------------------------

About Breast CancerOne in eight American women will have breast cancer during her lifetime. Breast cancer is the second leading cause of cancer death among American women. The American Cancer Society estimates in its Cancer Facts & Figures 2018 report that more than 250,000 women will be told they have breast cancer in 2018.

About Myriad myRisk® Hereditary Cancer The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 29 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

About riskScore ™riskScore is a new clinically validated personalized medicine tool that enhances Myriad’s myRisk® Hereditary Cancer test. riskScore helps to further predict a women’s lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About EndoPredict®EndoPredict is a second-generation, multigene prognostic test that aids personalized treatment planning for patients with early-stage breast cancer. EndoPredict has been validated in approximately 4,000 patients with node-negative and node-positive disease and has been used clinically in more than 25,000 patients. In contrast to first-generation multigene prognostic tests, EndoPredict is now validated to accurately predict both early (0-5) and late (5-15 years) distant recurrence and for prediction of benefit from both chemotherapy and extended endocrine therapy.

About myChoice HRD ™Myriad’s myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. High myChoice HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes, ovarian and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in certain patients with triple-negative breast and ovarian cancers.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and Prelude are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Company’s data across multiple genetic tests being featured at the San Antonio Breast Cancer Symposium being held Dec. 4-8, 2018 in San Antonio, Tx.; our progress in advancing precision medicine for women with breast cancer; and the Company’s strategic directives under the caption “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2018, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com

AP RADIO
Update hourly